Navigational Trip: Safety, Security, and Protection as Compliance to Interntional Standard

This study was determined the evaluation of the safety, security, and protection of the navigational trip in terms of safety among marine engineering students as an entire group and when they were classified according to section such as Polaris 3-A, Polaris 3-B, and Polaris 3-C. Respondents of the study were the one hundred twenty (120) Polaris marine engineering students who are currently enrolled in the College of Maritime Education of JBLFMU-Molo for School Year 2017-2018 who were on board or have undertaken the navigational trip and have observed some of the safety and security services on board. The researchers employed quantitative-qualitative research design by Creswell (2013) to determine the navigational trip and observations of the safety and security services on board. Results revealed that the respondents had “excellent evaluation” about the safety, protection, and security of the navigational trip vessel. There were no significant differences in the evaluation of the respondents as to the different sections; no relationships were observed when the respondents’ evaluation results were compared according to sections. The observations and comments cited in this study signify that the navigational trip vessel exhibited safety and security, maintain clean and safe environment, and followed the strict implementation of safety as prescribed by the international standards. The respondents’ comments attested that the navigational ship has implemented the international standard of safety and procedure on board

Computer-Based Training (CBT): Innovation and Influence Towards Teaching-Learning Process at JBLFMU-Molo

This study determined the level of assessment of subjects with CBT (Computer-Based-Training) application among marine engineering students of John B. Lacson Foundation Maritime University-Molo, Iloilo City. The participants in this study were the randomly selected one hundred and thirty-three (133) marine engineering students of JBLFMU-Molo, Iloilo City who had taken subjects with CBTs. The present study employed quantitative-qualitative research design by Creswell (2013). Results reveal the following: (1) review with CBT or CBTR review is the mostly utilized subject because this is needed in the marine engineering licensure examinations; (2) level of assessment of CBTs is excellent; (3) no significant differences in the assessment of CBTs were found out among marine engineering students as classified according to different variables such as academic performance, students’ classification, type of students, and section

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)